common.study.topics.clinical

Tenofovir Rectal Douche to Prevent HIV Transmission

common.study.values.description

Tenofovir Rectal Douche to Prevent HIV Transmission

DREAM-03 is an early phase-1, open label study to compare the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of 3 sequences of tenofovir (TFV) and non-medicated douches. The overall goal is to inform the design of an extended safety study of an on-demand and behaviorally congruent TFV douche to confer protection from HIV acquisition in an outpatient pre-RAI context.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Tenofovir douche

660 mg TFV in 125 mL hypo-osmolar solution

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase I, Open-label Multiple Dose Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Tenofovir Rectal Douche

common.study.values.clinical-trial-id

NCT04016233

participant.views.study.view.id

erkGpa